Dharam Ablashi

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Jump to: navigation, search
Source:LinkedIn

Dharam V. Ablashi, (b. 1931), DVM, MS, Dip. Bact. (Diploma in Bacteriology), Research Microbiologist, Head of DNA Viruses Section and Coordinator of DNA Viruses, National Cancer Institute.[1] He co-discovered HHV-6 in 1986, while working at the National Cancer Institute at National Institutes of Health and is the Scientific Director of the HHV-6 Foundation and Chair of the Scientific Advisory Committee.[2]

Awards[edit | edit source]

  • 2007, Rudy Perpich Senior Lectureship Award, presented to a distinguished CFS/FM scientist, physician or healthcare worker awarded by IACFS/ME[3]
  • 2007, Achievement Award from New Jersey CFS Association Inc.[4]

IACFSME[edit | edit source]

Ablashi co-founded the American Association of CFS with Orvalene Prewitt, in 1990.[5] The organization has been renamed as the International Association for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis with Ablashi serving as a past President of the Board of Directors from 2003-2004.[6]

Advocacy[edit | edit source]

CFSAC testimony[edit | edit source]

Written presentation by Dr. Ablashi on October 29, 2009:"It is imperative that the CDC study biopsy samples from the gut, and brain as well as heart tissues, and that they look at spinal fluid. Most of the studies done by the CDC have been on serum. However, many pathogens cannot be found in the serum because they do not circulate in the peripheral blood after the initial infection."[7]

Open letters to The Lancet[edit | edit source]

In response to The Lancet's publication of the controversial PACE trial in 2011, three open letters to the editor of The Lancet urged the editor, Richard Horton, to commission a fully independent review of the PACE trial. Dr. Ablashi signed the second and third letters. The first, written in 2015, was signed by six ME/CFS experts.[8] In 2016, thirty-six additional colleagues in the ME/CFS field, signed the second letter.[9] In 2018, a resubmitted letter had over one hundred signatories.[10]

Notable studies in ME/CFS[edit | edit source]

Online presence[edit | edit source]

See also[edit | edit source]

Learn more[edit | edit source]

References[edit | edit source]

  1. Ablashi, Dharam. "Dharam Ablashi - Scientific Director at HHV-6 Foundation". Linked In. 
  2. Ablashi, Dharam. "Scientific Office | HHV-6 Foundation | HHV-6 Disease Information for Patients, Clinicians, and Researchers | Apply for a Grant". hhv-6foundation.org. Retrieved Aug 16, 2018. 
  3. "Former IACFS/ME Awardees". IACFS/ME. 
  4. "Dharam Ablashi". Wikipedia. Jun 9, 2018. 
  5. "History of the IACFS/ME". IACFS/ME. 
  6. "Committees of the IACFS/ME". IACFS/ME. 
  7. "Biologisch Medisch Centrum | Dharam Ablashi Human Herpes Virus 6A (HHV-6 A) CFS/ME | Paul van Meerendonk Utrecht Epe". biologischmedischcentrumbmc.nl. Retrieved Aug 16, 2018. 
  8. "An open letter to Dr. Richard Horton and The Lancet". www.virology.ws. Retrieved Aug 16, 2018. 
  9. "An open letter to The Lancet, again". www.virology.ws. Retrieved Aug 16, 2018. 
  10. "Trial By Error: Yet Another Appeal to The Lancet, With More On Board". www.virology.ws. Retrieved Aug 16, 2018. 
  11. Tuller, David (Nov 13, 2015). "An open letter to Dr. Richard Horton and The Lancet". www.virology.ws. Retrieved Aug 16, 2018. 
  12. Tuller, David (Feb 10, 2016). "An open letter to The Lancet, again". www.virology.ws. Retrieved Aug 16, 2018. 
  13. Tuller, David (Jul 10, 2018). "Trial By Error: Yet Another Appeal to The Lancet, With More On Board". www.virology.ws. Retrieved Aug 16, 2018. 
  14. Buchwald, Dedra; Cheney, Paul R.; Peterson, Daniel L.; Henry, Berch; Wormsley, Susan B.; Geiger, Ann; Ablashi, Dharam V.; Salahuddin, S. Zaki; Saxinger, Carl; Biddle, Royce; Kikinis, Ron; Jolesz, Ferenc A.; Folks, Thomas; Balachandran, N.; Peter, James B.; Gallo, Robert C.; Komaroff, Anthony L. (1992), "A chronic illness characterized by fatigue, neurologic and immunologic disorders, and active human herpesvirus type 6 infection", Annals of Internal Medicine, 116 (2): 103-113, PMID 1309285 
  15. Levine, Paul H.; Jacobson, Steven; Pocinki, Alan G.; Cheney, Paul; Peterson, Daniel; Connelly, Roger R; Weil, R; Robinson, SM; Ablashi, Dharam V; Salahuddin, Sayeef Z; Pearson, GR; Hoover, R (1992), "Clinical, Epidemiologic, and Virologic Studies in Four Clusters of the Chronic Fatigue Syndrome", Archives of Internal Medicine, 152 (8): 1611-1616, doi:10.1001/archinte.1992.00400200049009 
  16. Ablashi, DV; Berneman, ZN; Williams, M; Strayer, D; Kramarsky, B; Suhadolnik, RJ; Reichenbach, N; Hiltzges, P; Komaroff, AL (1994), "Ampligen inhibits human herpesvirus-6 in vitro", In Vivo, 8 (4): 587-91, PMID 7893986 
  17. Strayer, DR; Carter, W; Strauss, KI; Brodsky, I; Suhadolnik, R; Ablashi, D; Henry, B; Mitchell, WM; Bastien, S; Peterson, D (1995), "Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen", Journal of Chronic Fatigue Syndrome, 1 (1): 35-53, doi:10.1300/J092v01n01_04 
  18. Wagner, Mathias; Krueger, Gerhard R. F.; Ablashi, Dharam V.; Whitman, James E. (1996), "Chronic Fatigue Syndrome (CFS): A Critical Evaluation of Testing for Active Human Herpesvirus-6 (HHV-6) Infection, Review of Data of 107 Cases", Journal of Chronic Fatigue Syndrome, 2 (4): 3-16, doi:10.1300/J092v02n04_02 
  19. Ablashi, Dharam V.; Ablashi, Kristine L.; Kramarsky, Bernhard; Bernbaum, John; Whitman, James E.; Pearson, Gary R. (1995), "Viruses and Chronic Fatigue Syndrome: Current Status", Journal of Chronic Fatigue Syndrome, 1 (2): 4-22, doi:10.1300/J092v01n02_02 
  20. Levine, Susan; Eastman, Helen; Ablashi, Dharam V. (2001), "Prevalence of IgM and IgG Antibody to HHV-6 and HHV-8 and Results of Plasma PCR to HHV-6 and HHV-7 in a Group of CFS Patients and Healthy Donors", Journal of Chronic Fatigue Syndrome, 9 (1-2): 31-40, doi:10.1300/J092v09n01_04 
  21. Cameron, Barbara; Hirschberg, David L.; Rosenberg-Hassan, Yael; Ablashi, Dharam; Lloyd, Andrew R. (2010), "Serum Cytokine Levels in Postinfective Fatigue Syndrome", Clinical Infectious Diseases, 50 (2): 278-280, doi:10.1086/649546 

Chronic fatigue syndrome advisory committee (CFSAC) - (sometimes pronounced SIF-SACK) A US government advisory council that met twice per year, covering current topics related to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Meetings usually lasted for two days and the results were presented to the Secretary of Health and Human Services (HHS). After 15 years, on September 5, 2018, CFSAC's charter was not renewed by the Department of HHS, effectively dissolving the committee without notice or warning.

serum - the clear yellowish fluid that remains from blood plasma after clotting factors have been removed by clot formation

ME/CFS - An acronym that combines myalgic encephalomyelitis with chronic fatigue syndrome. Sometimes they are combined because people have trouble distinguishing one from the other. Sometimes they are combined because people see them as synonyms of each other.

Antibody - Antibodies or immunoglobulin refers to any of a large number of specific proteins produced by B cells that act against an antigen in an immune response.

serum - the clear yellowish fluid that remains from blood plasma after clotting factors have been removed by clot formation

Myalgic encephalomyelitis (ME) - A disease often marked by neurological symptoms, but fatigue is sometimes a symptom as well. Some diagnostic criteria distinguish it from chronic fatigue syndrome, while other diagnostic criteria consider it to be a synonym for chronic fatigue syndrome. A defining characteristic of ME is post-exertional malaise (PEM), or post-exertional neuroimmune exhaustion (PENE), which is a notable exacerbation of symptoms brought on by small exertions. PEM can last for days or weeks. Symptoms can include cognitive impairments, muscle pain (myalgia), trouble remaining upright (orthostatic intolerance), sleep abnormalities, and gastro-intestinal impairments, among others. An estimated 25% of those suffering from ME are housebound or bedbound. The World Health Organization (WHO) classifies ME as a neurological disease.

The information provided at this site is not intended to diagnose or treat any illness.
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history.